• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Lumito

2.75 SEK

+7.65 %

Less than 1K followers

LUMITO

NGM Growth Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+7.65 %
-1.96 %
-36.53 %
-60.79 %
-65.69 %
-96.68 %
-99.25 %
-99.28 %
-98.87 %

Lumito is a Swedish company that develops and markets systems for tissue and biomarker analysis in digital pathology, built on upconverting nanoparticle technology. The company targets healthcare facilities, research and the pharmaceutical sector. The company was formed in 2010 as a spinoff from a research group at Lund University's Department of Atomic Physics and Laser Center. Lumito is headquartered in Lund.

Read more
Market cap
9.45M SEK
Turnover
20.03K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
7/7
2026

Extraordinary general meeting '26

20/8
2026

Interim report Q2'26

29/10
2026

Interim report Q3'26

Press release6/11/2026, 2:09 PM

Analyst Group: Analyst Group kommenterar Lumitos utökning av Scientific Advisory Board

Lumito
Regulatory press release6/11/2026, 11:00 AM

Lumito stärker Scientific Advisory Board med internationellt ledande experter inom life science och läkemedelsutveckling

Lumito
Regulatory press release6/11/2026, 11:00 AM

Lumito strengthens Scientific Advisory Board with internationally leading experts in life science and drug development

Lumito

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release6/9/2026, 6:30 AM

Teckningsoptioner av serie TO7 tecknades till cirka 3,8 procent och Lumito tillförs cirka 254 TSEK

Lumito
Press release6/4/2026, 1:25 PM

Analyst Group: Analyst Group kommenterar Lumitos företrädesemission om ca 30 MSEK

Lumito
Regulatory press release6/4/2026, 6:30 AM

Information om pågående optionsinlösen

Lumito
Regulatory press release6/4/2026, 6:22 AM

KALLELSE TILL EXTRA BOLAGSSTÄMMA I LUMITO AB (PUBL)

Lumito
Regulatory press release6/4/2026, 6:20 AM

Styrelsen i Lumito AB beslutar om en företrädesemission om cirka 30 MSEK, villkorat av extra bolagsstämmas godkännande, för att tillvarata Bolagets kommersiella momentum och skapa långsiktigt värde

Lumito
Regulatory press release5/27/2026, 7:00 AM

Lumito awarded Vinnova funding to strengthen regulatory and quality capabilities during commercialisation

Lumito
Regulatory press release5/27/2026, 7:00 AM

Lumito beviljas Vinnova‑stöd för kompetens- och kvalitetsutveckling i kommersialiseringsfas

Lumito
Regulatory press release5/25/2026, 12:15 PM

Teckningskurs för nyttjandet av teckningsoptioner av serie TO7 i Lumito AB har fastställts till 3,5 SEK per aktie och nyttjandeperioden inleds idag den 25 maj 2026

Lumito
Regulatory press release5/25/2026, 12:15 PM

Subscription price for the exercise of warrants of series TO7 in Lumito AB has been set at 3.5 SEK per share, and the exercise period begins today, 25 May 2026

Lumito
Press release5/12/2026, 11:53 AM

Analyst Group: Aktieanalys på Lumito - Partnerdriven kommersialisering tar form

Lumito
Press release5/8/2026, 7:51 AM

Analyst Group: Analyst Group kommenterar Lumitos Q1-rapport

Lumito
Regulatory press release5/7/2026, 10:00 AM

Årsstämma i Lumito AB (publ) den 7 maj 2026

Lumito
Regulatory press release5/7/2026, 6:30 AM

Lumito AB publicerar kvartalsrapport 1, 2026

Lumito
Regulatory press release5/7/2026, 6:30 AM

Lumito AB publishes Interim Report Q1 2026

Lumito
Regulatory press release5/5/2026, 9:00 AM

Inbjudan till webbinarium i samband med Lumito AB:s delårsrapport Q1 2026

Lumito
Regulatory press release5/5/2026, 9:00 AM

Invitation to webinar in connection with Lumito AB’s interim report for Q1 2026

Lumito
Press release5/4/2026, 10:05 AM

Analyst Group: Analyts Group kommenterar Lumitos nya white paper med Atlas Antibodies – färre processteg, bibehållen analytisk prestanda

Lumito